US EditionMabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
- Mabwell announced clinical data for three antibody-drug conjugates to be presented at the 2025 ASCO Annual Meeting in Shanghai.
- These presentations follow phase Ib/II studies including 9MW2821 combined with Toripalimab for advanced urothelial carcinoma, and poster data of 7MW3711 and 9MW2921 in advanced solid tumors.
- The 9MW2821 study enrolled 40 untreated patients treated with 1.25 mg/kg 9MW2821 and 240 mg Toripalimab, showing an 87.5% objective response rate and 92.5% disease control rate as of December 19, 2024, without new safety signals.
- The 7MW3711 trial reported no dose-limiting toxicity, with an overall response rate of 36.0% at doses ≥4.5 mg/kg and 62.5% ORR in small-cell lung cancer patients, while 9MW2921 showed 42.1% ORR with common grade 3 events including stomatitis and anemia.
- These results support ongoing pivotal trials and regulatory designations, highlighting Mabwell's innovation-driven pipeline and comprehensive drug development capabilities in oncology.
13 Articles
13 Articles
thepilotnews.com
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
SHANGHAI, May 23, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clinical study…
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting - PressReach
SHANGHAI, May 23, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clinical study data of 9MW2821 (Bulumtatug Fuvedotin, BFv), a novel Nectin-4 targeting ADC, in combination with Toripalimab in locally advanced or metastatic u…
Coverage Details
Bias Distribution
- 40% of the sources are Center, 40% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
